Patient Square Capital portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 12, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Patient Square Capital reported a $646M portfolio of 23 positions to the SEC as of the end of Q2 2026. Its largest positions are ROIV, RVMD, MIRM. During the quarter it opened Revolution Medicines and United Therapeutics and exited Insmed and Legend Biotech.
Sections with a free account
What changed this quarter
35 positions with a change (6 new, 9 added to, 8 trimmed, 12 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Revolution Medicines+8.0 ppof portfolioNew— → 8.0%
- Insmed−4.0 ppof portfolioSold out4.6% → —
- United Therapeutics+3.1 ppof portfolioNew— → 3.1%
- Legend Biotech−2.8 ppof portfolioSold out3.2% → —
- Nektar Therapeutics−2.3 ppof portfolioSold out2.7% → —
- Argenx−37%fewer sharesReduced4.8% → 3.3%
- BioNTech+1.9 ppof portfolioNew— → 1.9%
- Abivax+70%more sharesIncreased2.4% → 4.3%
- Celcuity−1.7 ppof portfolioSold out1.9% → —
- Merck−1.5 ppof portfolioSold out1.7% → —
- C4 Therapeutics+1.2 ppof portfolioNew— → 1.2%
- Inventiva+1.2 ppof portfolioNew— → 1.2%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Roivant SciencesROIV44.0%
- Revolution MedicinesRVMD8.0%
- Mirum PharmaceuticalsMIRM4.7%
- AbivaxABVX4.3%
- Beone MedicinesONC4.0%
- PharvarisPHVS3.6%
- ArgenxARGX3.3%
- United TherapeuticsUTHR3.1%
- Belite BioBLTE2.6%
- Cogent BiosciencesCOGT2.5%
- DBV TechnologiesDBVT2.3%
- Xenon PharmaceuticalsXENE2.1%
- BioNTechBNTX1.9%
- Arcus BiosciencesRCUS1.7%
- Enliven TherapeuticsELVN1.7%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 23
Q2 2026: 80%
Q2 2026: 22.3%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Private equity or venture capital, per its Form ADV of May 26, 2026 (low confidence).
The data, as reported: PATIENT SQUARE CAPITAL, LP (CRD 312203): 7.B private funds: 30 pe (gross assets $17.2 bn); 5.D assets by client type: pooled vehicles 100% (of $17.5 bn) · BUT its 13F has 23 positions and only 0% comes from IPOs: it may be a fund that also buys on the market; not enough to exclude it
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- JB Capital PartnersInvestment firm · $646M
- Broad Run Investment ManagementInvestment firm · $650M
- BlueSpruce InvestmentsInvestment firm · $650M
- Sprucegrove Investment ManagementInvestment firm · $639M
- Sunriver Management$637M
- Kahn Brothers GroupInvestment firm · $633M